The single nucleotide polymorphism (SNP), 2397G > T (rs13278062) polymorphism, in the promoter of Death Receptor 4 (DR4) had been reported to be associated with a significantly increased risk for bladder cancer. However, the association of this SNP with the risk of colorectal cancer has not been reported. In this study, we performed a case-control study in 1,078 colorectal cancer patients and 1,175 matched healthy controls to evaluate the association of the potential functional genetic variants in DR4 with risk and survival of colorectal cancer. PCR-TaqMan were used to genotype the rs13278062, rs1000294 and rs2235126 polymorphisms. We found that subjects carrying the rs13278062 GT/TT genotypes had a significantly lower risk and increased survival time when compared to the GG genotype. We also constructed the rs13278062 GT/TT genotype in SW480 and SW620 cells (rs13278062 is GG in both cell lines) with the CRISPR/Cas9 system. Flow cytometry experiments showed that the rs13278062 TT genotype promoted apoptosis in colorectal cancer cells. In vitro and in vivo experiments established that the rs13278062 G to T mutation inhibited carcinogenesis and metastasis of colorectal cancer. Chromatin immunoprecipitation (ChIP) assays revealed that the rs13278062 G > T polymorphism altered the binding affinity of the transcription factors Sp1/NF1 to the rs13278062 mutation region. Immunohistochemistry, western blot, and qPCR corroborated that the rs13278062 GT/TT genotypes increased the expression of DR4 protein in colorectal cancer tissues and cells. In conclusion, these findings indicate that DR4 mediated progression, invasion, metastasis and survival of colorectal cancer via the Sp1/NF1 switch axis on genomics locus.
studied. [7] [8] [9] Death receptor 4(DR4) contains a cytoplasmic death domain that activates apoptosis by interacting with tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) through the extrinsic death receptor pathway. The aberrant expression of DR4 has been observed in several human malignancies, including colorectal cancer 10 and pancreatic ductal adenocarcinoma. 11 Furthermore, it has been reported that abnormal expression of DR4 was also correlated with the prognosis of colorectal cancer 10 and lung squamous cell carcinoma. 12 Several functional single nucleotide polymorphisms (SNPs) in the DR4 gene are associated with different types of diseases, such as colorectal cancer, 13 prostate cancer, 14 ovarian cancer, 15 lung cancer and head and neck cancer, 16 However, the minor allele frequency (MAF) of these SNPs was low in Han Chinese individuals from Beijing, China (CHB populations), suggesting that other variants in DR4 might play an important role in the development of cancer. Wang et al. first reported that the SNP 2397G > T polymorphism in the promoter of DR4, which has a high MAF, was associated with a significantly increased risk of bladder cancer in a Chinese population. 17 However, the association between these SNPs and the risk of colorectal cancer has yet to be ascertained. Recently, a novel genetic engineering tool called CRISPR/ Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/Cas9) has been widely utilized, given its ease of generation and high efficiency gene editing. Moreover, HDR (homology-directed repair), one of the endogenous repair machineries for DSBs (the double-stranded DNA breaks) produced by the CRISPR/Cas9, can introduce specific point mutations in genomic loci with an exogenous DNA donor template carrying any of the desired changes. 18 Here, we performed a case-control study with 1,078 colorectal cancer patients and 1,175 matched healthy controls to validate the association of potential functional genetic variants with risk and survival of patients with colorectal cancer. We also explored the molecular mechanisms underlying the development of colorectal cancer mediated by functional genetic variants, specifically those with a high mutation rate in DR4.
Materials and Methods

Study subjects
A total of 1,277 newly diagnosed and histologically confirmed patients with colorectal cancer were recruited in the Jiangsu province (China) between January 2007 and October 2011. Healthy controls (1, 175) were randomly selected from individuals who sought routine physical examinations in the same district. All patients had no previous history of other cancers and the controls were genetically unrelated to the cancer cases. The sixth edition of the American Joint Committee on Cancer (AJCC) cancer staging manual was used to assess the pathological stage of patients with colorectal cancer. All patients were followed-up by a trained clinical specialist through personal or family contacts from the time of diagnosis to death or last follow-up (last follow-up in June 2016). The maximum follow-up time was 112.7 months and the median survival time (MST) was 75.0 months. Of the recruited patients, a total of 1,078 patients who had complete follow-ups were enrolled in the study, with a response rate of 84.4%. Informed consent was obtained from each enrolled subject before recruitment. The institutional Review Board (IRB) of Southeast University (Nanjing, China) approved this study.
Genotyping
The genomic DNA of controls was isolated from the venous blood using the RelaxGene Blood DNA System (Tiangen biotech, Beijing, China). For the cancer cases, paraffin-embedded tissues were used to extract the genomic DNA with the EZNA Tissue DNA Kit (Omega Bio-Tek, GA, USA), owing to lack of blood samples. TaqMan allelic discrimination assays were used to detect the genotypes of selected polymorphisms with the Quant Studio 6 Flex system (Applied Biosystems, CA, USA). The loading well without DNA was used as a negative control. Ten percentage of the samples was randomly selected to confirm the genotyping results. The concordance rate was 100%.
Immunohistochemistry (IHC)
The detailed procedure for the IHC assay had been previously described. 19 Briefly, the specimens were incubated with rabbit polyclonal anti-DR4 antibody (ab8414, Abcam, Cambridge, UK) overnight at 48C. All the specimens were stained with 3,3 0 -diaminobenzidine (DAB; Zhongshan Biotech, Beijing, China). The staining score for DR4 was calculated by two pathologists blinded to the results of the genotype by applying a semi quantitative immunoreactivity score (IRS) as reported previously. 20 What's new? Death receptor 4 (DR4) is a cell protein that can activate apoptosis (programmed cell death). Abnormal expression of DR4 is associated with poor prognosis in colorectal cancer (CRC). In this study, the authors found that when a particular SNP in the DR4 gene contained GT/TT, patients had a decreased risk of CRC and increased survival times compared to the GG genotype. The authors then used CRISPR/Cas9 to change GG to GT in CRC cells, and found that this change promoted apoptosis and inhibited carcinogenesis and metastasis in vivo.
Cell culture
Human colorectal cancer cells (SW480 and SW620) were purchased from the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China) and cultured in complete Dulbecco's Modified Eagle Medium (DMEM) (HyClone, Logan, UT, USA), 10% FBS (Sigma, ST. Louis, MO, USA) in 5% CO 2 at 378C. All media contained penicillin (100 U ml
21
)/streptomycin (100 lg ml 21 ) (HyClone, Logan, UT, USA). The cells were periodically tested and validated to be free of mycoplasma. All cell lines were tested by short tandem repeat analysis and used within 6 months.
Generation of mutation in colorectal cancer cells with CRISPR/cas9
The CRISPR/Cas9 expression vectors, expressing Cas9, sgRNA and puromycin resistant gene, were constructed based on the pX330 vector. The sequences for the sgRNA construct and single-stranded DNA donor are shown in Supporting Information, Figure s1 . The day before the transfection, we plated 2 3 10 5 cells per well, in six-well plates. A total of 1 lg CRISPR/Cas9 expression plasmid and 0.1 lg single-stranded DNA donor construct were then co-transfected into the cells with the Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA), in accordance with the manufacturer's protocol. After 24 hr, we replaced the culture medium with 2 ml of complete medium containing 0.6 lg ml 21 puromycin (VWR Pty Ltd, Brisbane, Australia), replacing it in every 2 days for the next 2 weeks. Surviving cells were then plated at a density of 1 cells per well in a 96-well plate to obtain colonies derived from single cells. To determine the allele-specific colonies, cells were ultimately harvested for DNA sequencing (Supporting Information, Fig. s1 ). Meanwhile, negative control group cells were co-transfected with CRISPR/Cas9 expression plasmid and the same wild-type ssDNA donor carrying with C allele (Supporting Information, Fig. s1 ). At this point, the negative colorectal cells were not edited on the genome.
Chromatin immunoprecipitation assay (ChIP)
Human peripheral white blood and colorectal cancer cells were used for ChIP assay with a ChIP-IT TM Express Magnetic Assay kit and ChIP-IT TM Control qPCR kit (Active Motif, Carlsbad, CA, USA) as described previously. 21 Briefly, the following antibodies were used for the immunoprecipitation reaction: Sp1, NF1, positive control RNA poly (Active Motif, Carlsbad, CA, USA) or negative control IgG (Active Motif, Carlsbad, CA, USA). The precipitated genomic DNA was analyzed by quantitative RT-PCR with the following DR4 promoter primers including the rs13278062 polymorphism: 5 0 -CCTCAGCCTTTCTGTGACCC-3 0 (forward) and 5 0 -AAATCGCTTGAACCTGGGAG-3 0 (reverse).
RNA extraction and qRT-PCR analysis
Total RNAs from the cell lines or tissues used in this study were extracted using the Trizol reagent (Invitrogen, US).
cDNA synthesis was performed with 1 lg total RNA according to the manufacturer's protocol (Takara, Japan). Cyclophilin A was used as internal controls in SYBRV R Green Realtime PCR Master Mix-Plus kits (Toyobo, Osaka, Japan). The relative RNA levels of DR4, DR5 and TRAIL were determined with the Quant Studio 6 Flex system (Applied Biosystems, Life Technologies, USA).
Western blot assay
Western blot assay was performed as described previously 21 . Briefly, total protein was loaded in each lane and transferred to a PVDF membrane (Bio-Rad, Hercules, CA, USA). The membrane was incubated overnight at 48C with DR4, DR5, TRAIL and a-tubulin primary antibody, and incubated with horseradish peroxidase (HRP)-conjugated goat secondary antibodies (BOSTER, Wuhan, China) for 1 hr at room temperature.
Expression plasmid construction and lentivirus stable transduction
Lentiviral expression plasmid that harbored a firefly luciferase cDNA and lentiviruses were generated as described previously. 22 Briefly, lentiviral particles were mixed gently, and added to colorectal cancer cells. After transduction with lentivirus for 12 hr, we replaced the culture medium with complete medium containing 7.5 lg ml 21 blasticidin S (InvivoGen, San Diego, CA, USA), and replaced it every 2 days for the next 1 week after all control cells died. Positive cells were maintained in 1 lg ml 21 blasticidin S for 2 weeks. For the experiments, cells were used prior to passage 15 from the initial drug selection.
Analysis of cell colony formation, invasion, migration ability and apoptosis
The detailed procedure for these assays has previously been described. 22 In brief, for colony formation assays, 500 colorectal cancer cells were seeded in 10 cm plates and allowed to grow in complete medium for 10 days. For the cell invasion assays, 1 3 10 5 cells were plated into the Transwell insert coated with Matrigel (CytoSelect 24-Well Cell Invasion Assay Kit; Cell Biolabs, USA), and cultured with complete medium for 48 hr. For cell migration assays, 1 3 10 5 cells were plated into the Transwell insert, and cultured with complete medium for 24 hr. Finally, all cells were fixed with ethanol and stained with crystal violet. For detection of apoptosis, cells were stained with Annexin V-FITC/PI at room temperature in the dark. The rate of apoptosis was analyzed by Flow cytometry. All assays were independently performed in triplicates.
Flank tumor growth in vivo nude experiments
All experiments were performed in accordance with the guidelines of the Committee on Animal Use and Care of Southeast University. A total of 36 nude mice (6 mice per each genotype cell) and 18 NCG (3 mice per each genotype Cancer Epidemiology cell) mice were used for both wild-type and CRISPR/cas9-mediated mutant colorectal cancer cell implantations. Mice were subcutaneously injected with 0.5 ml of cell suspension containing 5 3 10 6 cells on their left dorsal flanks or axilla.
The mice were killed 14 days after infection under ether anesthesia and tumor tissues were removed for further analysis. Tumor, liver and lung tissues were assayed for luciferase activity analysis with a luminometer (Sirius, Berthold Detection Systems, Germany).
Statistical analysis
The 
Results
Association between the selected polymorphisms and colorectal cancer susceptibility
The demographic and clinical information of the colorectal cancer cases and controls is summarized in Supporting Information, Table S1 . The frequency distributions of age and gender of the cases and controls were comparable (p 5 0.599 and p 5 0.184, respectively). The association between the selected polymorphisms and colorectal cancer susceptibility are shown in Table 1 . Briefly, the genotype frequencies of the three polymorphisms (i.e., rs13278062, rs1000294 and rs2235126) among controls were all consistent with the Hardy-Weinberg equilibrium (all p > 0.05). Only the rs13278062 genotype distributions were significantly associated with the risk of colorectal cancer (p 50.0228) ( Table 1) . Specifically, the dominant genetic model showed a significantly decreased risk of colorectal cancer after adjusting for age and gender (GT/TT versus GG, p 5 0.0066, adjusted OR 5 0.79, 95% CI 5 0.67-0.94). Furthermore, subjects carrying the GT/TT genotypes showed a significantly decreased risk compared with those carrying the GG genotype in stratified analysis (Supporting Information, Table s2 In addition, no significant differences were found in this study between the risk of colorectal cancer and the other two SNPs.
DR4 rs13278062 polymorphism and colorectal cancer survival
The demographic and survival information for the colorectal cancer patients are shown in Supporting Information, Table s3 . Table 2 and Fig. 1ab , the GT/TT genotypes were associated with a significantly increased survival time when compared with the GG genotype (log-rank p 5 0.0006, adjusted HR 5 0.82, 95% CI 5 0.70-0.96).
As shown in
In the stratified analysis (Supporting Information, Table s4), the GT/TT genotypes were significantly associated with a favorable survival time among the male subgroups (adjusted HR 5 0.80, 95% CI 5 0.66-0.97). In addition, the subgroups of low differentiated, TNM stages III and IV displayed an analogous result (adjusted HR 5 0.75, 95% CI 5 0.57-0.97; adjusted HR 5 0.78, 95% CI 5 0.62-0.98 and adjusted HR 5 0.59, 95% CI 5 0.39-0.91, respectively).
rs13278062 TT genotype promotes apoptosis in colorectal cancer cells
Inspired by the populations results, we assumed that rs13278062 G > T polymorphism within the DR4 promoter was likely to be functional. Accumulating studies have shown that DR4 might activate apoptosis by interacting with TRAIL through the extrinsic death receptor pathway. Next, we analyzed the levels of cell apoptosis in both wild-type and CRISPR/cas9-mediated rs13278062 mutant colorectal cancer cells. Interestingly, the CRISPR/cas9-mediated rs13278062 mutant colorectal cancer cells showed higher levels of cell apoptosis than the wild-type cells (Fig. 2) . 
Effects of rs13278062 TT genotype on colorectal cancer cell phenotypes
We then evaluated the effects of the variants in the DR4 gene on colorectal cancer cell phenotypes with the CRISPR/ cas9-mediated mutant colorectal cancer cells. Interestingly, the CRISPR/cas9-mediated rs13278062 mutant colorectal cancer cells showed lower levels of cell colony-formation ability than the wild-type cells (Fig. 3ab) .
Moreover, as shown in Fig. 3cd , migration and invasion ability were suppressed in both types of CRISPR/cas9-mediated rs13278062 mutant colorectal cancer cells. Consistent with the in vitro experiments, the CRISPR/cas9-mediated mutant colorectal cancer cells showed lower levels of tumor sizes, liver and lung metastasis compared with the wild-type cells both in nude or NCG mice (Fig. 3ef and Supporting Information, Fig. s2 ).
rs13278062 GT/TT genotype decreased the binding affinity of Sp1 and NF1 to the DR4 promoter Given that the SNP 2397G > T polymorphism was located in the promoter region of DR4, we then analyzed the promoter region surrounding the DR4 rs13278062 G > T polymorphism, using a bioinformatics algorithm (AliBaba2). We found that the rs13278062 G > T polymorphism changed the binding affinity of Sp1/NF1 to the rs13278062 mutation region (Fig. 4a) . To corroborate this finding, we evaluated the genotype-specific binding affinity of Sp1/NF1 on the DR4 promoter with the ChIP assay ( Fig. 4bg and Supporting Information, Fig. s3a-c) . As shown in Figure 4bg , the antiSp1 was preferentially recruited to the GG genotype of rs13278062 than the TT genotype. In addition, similar to our finding in AliBaba2, the rs13278062 GG genotype failed to bind to NF1.
rs13278062 TT genotype increased DR4 protein expression
We then evaluated the association between the rs13278062 G > T polymorphism and DR4 expression levels in colorectal cancer cells, fresh tissues and paired paraffin sections (n 5 100). We found that DR4 mRNA and protein were up regulated in GT/TT mutant colorectal cancer cells compared with GG wildtype cells (Fig. 5ab) . IHC assay shown that most of DR4 protein was detected in the membrane in both colorectal cancer and normal tissue (Fig. 5c) . Furthermore, patients carrying with GT/ TT genotypes also showed an increased DR4 mRNA and protein levels in colorectal cancer tissues (Fig. 5de) . We also attempt to confirm those results in paired TMAs of colorectal cancer involving in our study. However, we observed an opposite result in protein levels of colorectal cancer paraffin sections in followed ISH assay (Supporting Information, Fig. S3D,E) .
Next, we detected DR5 and TRAIL mRNA and protein expression in wild-type and mutant colorectal cancer cells. However, no changes were noted in DR5 and TRAIL mRNA and protein levels (Supporting Information, Fig. s3f-i ).
Discussion
In this study, we found that subjects carrying the rs13278062 GT/TT genotypes had a significantly decreased risk and increased survival times when compared with those carrying the GG genotype. Further, functional assays revealed that the rs13278062 G > T polymorphism changed the binding affinity of the transcription factors Sp1/NF1 to the rs13278062 mutation region, leading to higher expression of DR4, and ultimately arresting the development of colorectal cancer.
Recent studies have shown that the SNPs in the DR4 gene are associated with different types of cancers, such as colorectal cancer, 13 prostate cancer, 14 ovarian cancer, 15 lung cancer and head and neck cancer. 16 To the best of our knowledge, the findings reported herein establish for the first-time decreased risk and increased survival times in colorectal cancer patients carrying the rs13278062 GT/TT genotype. Moreover, in the stratified analysis, similar results were observed in subjects with lymph node and distant metastasis. These results indicate that the rs13278062 polymorphism might be associated with the migration and invasion of colorectal cancer. Corroborating the above in vivo findings, in vitro experiments showed that the CRISPR/ Cas9-mediated rs13278062 G to T mutation also decreased colony formation, migration and invasion ability of colorectal cancer cells. Furthermore, in in vivo nude mice experiments, the rs13278062 G to T mutation significantly inhibited the tumorigenesis of colorectal cancer cells. However, the genotype frequencies of the rs13278062 polymorphism were inconsistent with results found in bladder cancer, 17 suggesting that different molecular mechanisms of the rs13278062 polymorphism might be involved in the etiology of distinct types of cancer. In addition, we failed to note any significant association between the risk of colorectal cancer and the DR4 rs1000294 and rs2235126 polymorphisms. This finding indicates that these two variants are likely not involved in the development of colorectal cancer. Death receptor 4 (DR4), also known as tumor necrosis factor receptor superfamily member 10 A (TNFRSF10A), is a cell surface receptor that might activate apoptosis by interacting with TRAIL through the extrinsic death receptor pathway. Accumulating evidence corroborates that the aberrant expression of DR4 is inherent to a plethora of human malignancies, including colorectal cancer 10 and pancreatic ductal adenocarcinoma. 11 Furthermore, it has been reported that abnormal expression of DR4 is also correlated with the prognosis of colorectal cancer 10 and lung squamous carcinoma cell patients. 12 Liu et al. reported that the expression of DR4 might be up regulated in a P53-dependent manner. 23 Herein, we found that rs13278062 GT/TT genotypes increased DR4 expression by affecting the binding affinity of Sp1 and NF1 to the DR4 promoter in colorectal cancer cells. Previous studies have shown that Sp1 is a transcriptional repressor.
24 NF1, however, was reported as a transcriptional activator. 25 Taken together, we speculate herein that NF1 might activate the membrane related DR4, and ultimately promote apoptosis of colorectal cancer cells. Regretfully, we observed an opposite result in DR4 protein levels in followed TMAs ISH assay. These findings indicate the weakness of ISH assay for timeworn TMAs, especially when it was used for quantifying the localization and the expression level of membrane protein. Thus, we proposed that ISH assay based upon the fresh tissues might be applicable to explore the location of gene expression. DR4 and DR5 are two receptors known to interact with TRAIL and transduce apoptosis. Herein, we establish, for the first time, that the CRISPR/cas9-mediated mutant colorectal cancer cells showed higher levels of cell apoptosis than the wild-type cells. Thus, we posit that DR4 promotes cell apoptosis in colorectal cancer by competitive binding with TRAIL in CRISPR/cas9-mediated mutant colorectal cancer cells. Previous study has shown that DR5 has a higher affinity for TRAIL as compared with DR4. 26 It have been reported that human DR5 promoted tumor growth, migration, invasion and metastasis. 27, 28 Thus, we speculate that higher expression of DR4 might counteract the DR5-mediated carcinogenic effect. Moreover, we did not observed any changes of DR5 and TRAIL mRNA and protein levels in wild type and CRISPR/cas9-mediated colorectal cells. Taken together, we propose that DR4 might play an important role in the development and prognosis of colorectal cancer.
In conclusion, we report that DR4 is associated with progression, invasion, metastasis and survival of colorectal cancer through the Sp1/NF1 switch axis on the genomic locus. Further functional studies are required to confirm our findings.
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